300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Social Impact
Oil and Gas
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Theatre
Transportation
Enterprise
Medical
Community
Media (Entertainment)
Recruiting
Web3
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
South Korea
Croatia
Burkina Faso
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Puerto Rico
Oman
Poland
Cameroon
Guernsey
Sudan
Andorra
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Argentina
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Bangladesh
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotech Startup Investors in Asia (August 2026)

The most active venture capital funds and angel investors investing in Asia Biotech startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Asia Biotech startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Qiming Venture Partners
VC Fund
82 China, United States, Hong Kong Series B, Series A, Series C Health Care, Biotechnology, Medical $5M–$134M
HSG
VC Fund
43 China, United States, Australia Series B, Series A, Seed Artificial Intelligence, Biotechnology, Software $2M–$282M
BioVenture
VC Fund
40 China, United States, Hong Kong Series A, Series B, Seed Health Care, Medical, Biotechnology $3.8M–$73M
Lilly Asia Ventures
VC Fund
33 China, United States, Hong Kong Series A, Series B, Series C Biotechnology, Health Care, Medical $14M–$308M
Med-Fine Capital
VC Fund
31 China, Hong Kong, United States Series A, Seed, Series B Medical, Health Care, Biotechnology $2.8M–$60M
Matrix Partners China
VC Fund
31 China, United States, Singapore Series A, Series B, Seed Health Care, Software, Artificial Intelligence $2.8M–$137M
Kaitai Capital
VC Fund
30 China, United States, Singapore Series A, Series B, Seed Biotechnology, Health Care, Pharmaceutical $1.4M–$57M
Frees Fund
VC Fund
29 China, United States, Singapore Series A, Seed, Angel Artificial Intelligence, Health Care, Biotechnology $425k–$35M
Legend Capital
VC Fund
27 China, United States, South Korea Series B, Series A, Series C Health Care, Medical, Biotechnology $2.9M–$200M
SMBC Venture Capital
VC Fund
26 Japan, United States, Singapore Series A, Series B Information Technology, Software, Health Care $1.5M–$184M
IDG Capital
VC Fund
26 China, United States, India Series A, Series B, Series C Software, Internet, E-Commerce $3M–$310M
Seeds Capital
VC Fund
26 Singapore, United States, Hong Kong Seed, Series A, Series B Biotechnology, Artificial Intelligence, Health Care $767k–$45M
Mitsubishi UFJ Capital
VC Fund
24 Japan, United States, Singapore Series A, Series B Information Technology, Software, Health Care $1.2M–$198M
Northern Light Venture Capital
VC Fund
23 China, United States, South Korea Series A, Series B, Seed Health Care, Medical, Biotechnology $1.3M–$100M
Sherpa Healthcare Partners
VC Fund
22 China, United States, Kenya Series A, Series B, Series C Biotechnology, Health Care, Medical $7.2M–$128M
ANRI
VC Fund
21 Japan, United States, Indonesia Seed, Series A Software, Medical, Health Care $413k–$41M
Linear Capital
VC Fund
21 China, Singapore, Switzerland Seed, Angel, Series A Artificial Intelligence, Software, Manufacturing $1.4M–$122M
Longpan Investment
VC Fund
21 China, United States, Cayman Islands Series A, Series B, Seed Health Care, Medical, Biotechnology $14M–$60M
UntroD Capital
VC Fund
20 Japan, Singapore, Austria Seed, Series A Manufacturing, Biotechnology, Health Care $772k–$90M
Shenzhen Capital Group
VC Fund
19 China, United States, Japan Series A, Series B, Series C Manufacturing, Health Care, Software $1.6M–$156M
Green Pine Capital Partners
VC Fund
19 China, United States, Canada Series A, Angel, Series B Artificial Intelligence, Biotechnology, Health Care $425k–$150M
CDH Investments
VC Fund
19 China, United States, Canada Series A, Series B, Series C Manufacturing, Health Care, Biotechnology $7.3M–$220M
Highlight Capital
VC Fund
19 China, United States, South Korea Series A, Series B, Seed Health Care, Medical, Biotechnology $2.8M–$84M
Osaka University Venture Capital
VC Fund
18 Japan Seed, Series A Biotechnology, Health Care, Medical $1.8M–$49M
Puhua Capital
VC Fund
18 China, United Kingdom, United States Series A, Series B, Seed Health Care, Medical, Manufacturing $1.4M–$103M
TF Capital
VC Fund
18 China, United States Series A, Series B, Series C Biotechnology, Health Care, Medical $7M–$1.4B
Fast Track Initiative, Inc.
VC Fund
18 Japan, United States, United Kingdom Series A, Series B, Seed Health Care, Biotechnology, Medical $345k–$117M
Hillhouse Investment
VC Fund
18 China, United States, Singapore Series B, Series A, Series C Biotechnology, Health Care, Software $2.9M–$230M
Gaorong Capital
VC Fund
17 China, United States, Hong Kong Series A, Series B, Seed Information Technology, Software, Artificial Intelligence $2.8M–$110M
Delian Capital
VC Fund
17 China, United States, France Series A, Seed, Series B Biotechnology, Health Care, Manufacturing $1.5M–$50M
Addor Capital
VC Fund
17 China, Hong Kong, Singapore Series A, Series B, Seed Manufacturing, Semiconductor, Electronics $1.4k–$47M
Cowin Capital
VC Fund
16 China, Hong Kong, United States Series A, Series B, Seed Manufacturing, Health Care, Biotechnology $1.4M–$51M
Prox Ventures
VC Fund
16 China, United States, United Kingdom Seed, Series A Medical, Biotechnology, Health Care $2.5M–$28M
Pan-Lin Capital
VC Fund
16 China, United States, Canada Series A, Seed, Series B Health Care, Biotechnology, Medical $1.4k–$58M
UTEC - The University of Tokyo Edge Capital Partners
VC Fund
15 Japan, United States, India Seed, Series A, Series B Health Care, Biotechnology, Medical $2.5M–$100M
CD Capital
VC Fund
15 China, United States Series A, Series B, Seed Health Care, Biotechnology, Medical Device $1.4M–$34M
Keio Innovation Initiative
VC Fund
14 Japan, United Kingdom Series A, Seed Health Care, Medical, Biotechnology $826k–$64M
Hillhouse Ventures
VC Fund
14 China, Singapore, Norway Series A, Series B, Seed Manufacturing, Biotechnology, Health Care $10M–$120M
K2VC
VC Fund
14 China, United States, Japan Series A, Seed, Angel E-Commerce, Manufacturing, Biotechnology $425k–$50M
Oriental Fortune Capital
VC Fund
14 China, United States Series A, Series B, Seed Software, Manufacturing, Information Technology $1.4M–$100M
Baidu Ventures
VC Fund
14 China, United States, Singapore Series A, Seed, Series B Artificial Intelligence, Health Care, Biotechnology $1.4M–$145M
Shunwei Capital
VC Fund
14 China, United States, India Series A, Series B, Series C Manufacturing, Software, Internet $1.4M–$130M
Beijing Huafang Investment
VC Fund
14 China Series A, Seed, Angel Biotechnology, Medical, Biopharma $13M–$30M
Legend Star
VC Fund
14 China, United States, France Series A, Seed, Angel Health Care, Medical, Biotechnology $425k–$52M
Taiyu Investment
VC Fund
14 China Seed, Series A, Angel Medical, Health Care, Biotechnology $4.1M–$29M
Cowin Venture
VC Fund
14 China, United States, Hong Kong Series A, Angel, Series B Health Care, Medical, Biotechnology $425k–$257M
SDIC Venture Capital
VC Fund
14 China, United States, Hong Kong Series B, Series A, Series C Manufacturing, Biotechnology, Electronics $2.8M–$129M
JAFCO
VC Fund
13 Japan, United States, Israel Series A, Series B Information Technology, Software, Artificial Intelligence $2.1M–$198M
BioTrack Capital
VC Fund
13 China, United States, Singapore Series A, Series B, Seed Biotechnology, Health Care, Medical $14M–$168M
ZhenFund
VC Fund
13 China, United States, Singapore Series A, Seed, Angel Artificial Intelligence, Software, E-Commerce $425k–$23M
Access all 50 investors in Asia Biotech startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Qiming Venture Partners
VC Fund · Shanghai, Shanghai, China · 82 investments in Asia Biotech startups

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 898
  • Round size: Series A $5M–$67M; Series B $9.4M–$100M; Series C $15M–$134M
  • Lead/follow: 45% lead, 55% follow
  • Last fund: Likely still investing — raised $887M in 2023

Portfolio highlights

  • Guangjing Energy — Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.
  • Talaris Therapeutics — Talaris seeks to help kidney transplant recipients and patients suffering from severe auto-immune diseases to live healthy lives free from chronic immunosuppression
  • Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Show all investments...

HSG
VC Fund · Hong Kong, Hong Kong Island, Hong Kong · 43 investments in Asia Biotech startups

HSG is a leading venture capital and private equity firm investing globally in the technology, healthcare, and consumer sectors.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Biotechnology, Software
  • Stage:Series B, Series A, Seed
  • Geography: China, United States, Australia

Investor stats

  • Total investments: 610
  • Round size: Seed $2M–$60M; Series A $10M–$100M; Series B $14M–$282M
  • Lead/follow: 41% lead, 59% follow

Portfolio highlights

  • Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/7a5aSCUfnr https://t.co/x14hb3jO7O
  • Full Truck Alliance — Full Truck Alliance is a platform that connects shippers with truckers to facilitate shipments across distance ranges and cargo weights. its revenues principally from shippers' and truckers' use of its platforms in connection with freight matching services.
  • Suisheng Technology — Suisheng Technology is an innovative company specializing in AI-driven memory services, dedicated to developing intelligent solutions that help individuals and businesses capture, organize, and retrieve important information with greater efficiency and precision.
Show all investments...

BioVenture
VC Fund · Suzhou, Jiangsu, China · 40 investments in Asia Biotech startups

Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 171
  • Round size: Seed $7.9M–$41M; Series A $3.8M–$47M; Series B $7.1M–$73M
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • Dami&Xiaomi — Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, andpopular science information.
  • CART Medical — CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.
  • MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
Show all investments...

Lilly Asia Ventures
VC Fund · Shanghai, Shanghai, China · 33 investments in Asia Biotech startups

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 221
  • Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
  • Lead/follow: 25% lead, 75% follow
  • Last fund: May invest from a new fund soon — raised $40M in 2019

Portfolio highlights

  • Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
  • ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
  • Abogen Biosciences — Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Show all investments...

Med-Fine Capital
VC Fund · Shanghai, Shanghai, China · 31 investments in Asia Biotech startups

Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.

Show more...

Investment focus

  • Industry: Medical, Health Care, Biotechnology
  • Stage:Series A, Seed, Series B
  • Geography: China, Hong Kong, United States

Investor stats

  • Total investments: 83
  • Round size: Seed $8M–$60M; Series A $2.8M–$40M; Series B $11M–$60M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $69M in 2019

Portfolio highlights

  • Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
  • Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
  • Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Show all investments...

Matrix Partners China
VC Fund · Beijing, Beijing, China · 31 investments in Asia Biotech startups

Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.

Show more...

Investment focus

  • Industry: Health Care, Software, Artificial Intelligence
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 499
  • Round size: Seed $2.8M–$98M; Series A $3M–$61M; Series B $10M–$137M
  • Lead/follow: 34% lead, 66% follow

Portfolio highlights

  • Lexin — LexinFintech Holdings is an online consumer finance platform for educated young adults in China. As one of China's leading financial technology companies, Lexin integrates its e-commerce-driven installment finance platform, Fenqile, with advanced risk management technologies, the Company's Dingsheng online investment platform, and theCompany's Juzi Licai online investment platform for individual investors, to create a comprehensive consumer finance ecosystem. The Company utilizes technologies including big data, cloud computing and artificial intelligence to enable the near-instantaneous matching of user funding requests with offers from the Company's more than 30 funding partners, which include commercial banks, consumer finance companies, and other licensed financial institutions. By serving the credit needs of China's educated young adults, Lexin helps its more than 20 million registered users to enjoy a better quality of life through the use of better credit.
  • Huangbaoche — Huangbaoche is a travel service providing tour packages and booking services. Huangbaoche has over 100,000 Chinese-speaking drivers and tour guides providing airport pick-up services, chartered car services, and guided tours in over 1,500 overseas travel destination cities in 80 countries.
  • Nuance Biotech — Nuance Biotech is a pharmaceutical company Based In China.
Show all investments...

Kaitai Capital
VC Fund · Hangzhou, Zhejiang, China · 30 investments in Asia Biotech startups

KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 146
  • Round size: Seed $2.4M–$20M; Series A $1.4M–$35M; Series B $10M–$57M
  • Lead/follow: 30% lead, 70% follow

Portfolio highlights

  • Aoquan — Aoquan is a biopharmaceutical company that provides research and development, production, and industrialization of innovative drugs.
  • Yushi Space — Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets.
  • Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Show all investments...

Frees Fund
VC Fund · Beijing, Beijing, China · 29 investments in Asia Biotech startups

By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Health Care, Biotechnology
  • Stage:Series A, Seed, Angel
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 216
  • Round size: Seed $1.4M–$14M; Angel $425k–$14M; Series A $1.4M–$35M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: May invest from a new fund soon — raised $130M in 2015

Portfolio highlights

  • SoundAI — Sound Technology is a science and technology innovation company that specializes in acoustics frontier technology and artificial intelligence interaction. It is committed to lead the more interactive experience of artificial intelligence in the real environment and realize the human-computer interaction vision that "listen to you and know whatyou think".
  • Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
  • Mask Network — Your Portal To The New, Open Internet.
Show all investments...

Legend Capital
VC Fund · Beijing, Beijing, China · 27 investments in Asia Biotech startups

Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, South Korea

Investor stats

  • Total investments: 427
  • Round size: Series A $2.9M–$100M; Series B $12M–$115M; Series C $15M–$200M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: Likely still investing — raised $177M in 2021

Portfolio highlights

  • Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/7a5aSCUfnr https://t.co/x14hb3jO7O
  • Pony.ai — Pony.ai is a startup that builds full-stack autonomous driving solutions. It is a pioneer in autonomous mobility technologies and services across the US and China, spearheading public-facing Robotaxi pilots in both markets. Pony.ai is committed to creating a safe and sustainable mobility future by delivering autonomous mobility everywhere.Thecompany was founded by James Peng and Tiancheng Lou in 2016 and is headquartered in Fremont, California, United States.
  • Jinqirui Biology — Jinqirui Biology is a biotechnology company that focuses on the research and development, manufacturing, production & sales of vitro diagnostics equipment and reagents.
Show all investments...

SMBC Venture Capital
VC Fund · Tokyo, Tokyo, Japan · 26 investments in Asia Biotech startups

Sumitomo Mitsui Banking Corporation (SMBC) and its group companies offer a broad range of financial services centered on banking. They are also engaged in the leasing, securities, credit card, investment, mortgage securitization, venture capital and other credit related businesses. The following lists the activities of SMBC, its subsidiaries andaffiliates in the various business segments.

Show more...

Investment focus

  • Industry: Information Technology, Software, Health Care
  • Stage:Series A, Series B
  • Geography: Japan, United States, Singapore

Investor stats

  • Total investments: 584
  • Round size: Series A $1.5M–$106M; Series B $3.1M–$184M
  • Lead/follow: 3% lead, 97% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • LQUOM — QWAVE offers cryptography communication technology.
  • Atom — Atom is a humanoid robot built platform. Its bipedal, dual-armed robots are designed not just as industrial tools but as collaborators that expand human capability. By combining advanced Physical AI—environmental perception, judgment, and action planning—with robust robotic hardware, Atom is creating adaptive agents capable of working acrossdiverse settings to augment or, where appropriate, replace human labor. The company positions these robots as a next step in societal evolution: a new class of machines that learn and behave in human-like ways to advance productivity, safety, and quality of life.
  • Link Therapeutics — Link Therapeutics specializes in developing therapeutic methods for targeting autoantibodies and identifying pathogenic autoantibodies.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
IDG Capital
VC Fund · Beijing, Beijing, China · 26 investments in Asia Biotech startups

IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.

Show more...

Investment focus

  • Industry: Software, Internet, E-Commerce
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, India

Investor stats

  • Total investments: 826
  • Round size: Series A $3M–$122M; Series B $8.5M–$142M; Series C $15M–$310M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: May invest from a new fund soon — last raise in 2017

Portfolio highlights

  • Hypershell — An exoskeleton innovator reshaping lifestyles and enabling technology to empower life.
  • Bivision — Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.
  • Youxi Film Hotel — Youxi Film Hotel which is a hotel in China that combines the perfect combination of hotel and movie IP. It is also a movie hotel theme, combining film derivative industry, movie theme social space and film shooting. An integrated creative culture complex; dedicated to creating a Chinese-style movie and hotel cross-border experience hotel, breakingthrough the traditional overnight function of a traditional hotel, creating the ultimate movie experience for young people with a mindset.
Show all investments...

Seeds Capital
VC Fund · Singapore, Central Region, Singapore · 26 investments in Asia Biotech startups

Catalysing smart monies into Singapore-based, early-stage technology startups.

Show more...

Investment focus

  • Industry: Biotechnology, Artificial Intelligence, Health Care
  • Stage:Seed, Series A, Series B
  • Geography: Singapore, United States, Hong Kong

Investor stats

  • Total investments: 146
  • Round size: Seed $767k–$6M; Series A $2.4M–$21M; Series B $5M–$45M
  • Lead/follow: 19% lead, 81% follow

Portfolio highlights

  • Pints AI — Unlock global and private financial data with AI like never before.
  • ChemT Biotechnology — The goal of ChemT Biotechnology is to increase patient access to the most cutting-edge biologics, beginning with the urgent issues in manufacturing and research and development.
  • Protuoso Biosciences — Protuoso Bio is a pioneering biotechnology company developing Next-Gen MUXBODIES for Complex Diseases. We leverage AI-driven protein engineering and synthetic biology to advance innovative oncology drug research.
Show all investments...

Mitsubishi UFJ Capital
VC Fund · Tokyo, Tokyo, Japan · 24 investments in Asia Biotech startups

Mitsubishi UFJ Capital is a venture capital firm focusing on life science, ICT, and high technology investments.

Show more...

Investment focus

  • Industry: Information Technology, Software, Health Care
  • Stage:Series A, Series B
  • Geography: Japan, United States, Singapore

Investor stats

  • Total investments: 576
  • Round size: Series A $1.2M–$74M; Series B $4.3M–$198M
  • Lead/follow: 5% lead, 95% follow
  • Last fund: May invest from a new fund soon — raised $1.4B in 2020

Portfolio highlights

  • ADiXi — Adixi is a tech-driven business that supports the idea that people and technology may work together. It strives to open doors by utilizing cutting-edge technology, such as artificial intelligence, to promote long-term, sustainable corporate and societal progress.
  • WARPSPACE — ARPSPACE is a space startup originating from the University of Tsukuba, has been launching and working on a satellite development project at the University of Tsukuba for five years until the company was established.
  • Luxna Biotech — Luxana Biotech is a biotechnology firm dedicated to promoting the practical use of safe and effective nucleic acid therapies. Utilizing nucleic acid chemistry technology, the company strives to provide nucleic acid medicines to patients suffering from diseases that currently lack effective treatments.
Show all investments...

Northern Light Venture Capital
VC Fund · Beijing, Beijing, China · 23 investments in Asia Biotech startups

Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, South Korea

Investor stats

  • Total investments: 274
  • Round size: Seed $1.3M–$100M; Series A $4.3M–$67M; Series B $11M–$62M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: Likely still investing — raised $375M in 2021

Portfolio highlights

  • Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
  • Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
  • Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
Show all investments...

Sherpa Healthcare Partners
VC Fund · Beijing, Beijing, China · 22 investments in Asia Biotech startups

Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Kenya

Investor stats

  • Total investments: 102
  • Round size: Series A $7.2M–$50M; Series B $15M–$100M; Series C $12M–$128M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • Shenfu Jianxing — Shenfu Jianxing is a brain-computer interface developer. It focuses on minimally invasive implanted brain-spinal interface technology, with "minimally invasive + low latency + high integration" as its core, to build implantable brain-spinal neural stimulation systems.
  • Yosemite Clinic — Yosemite Clinic is a full-service clinic providing convenient walk-in medical services in a state-of-the-art environment in Central Pudong. They offer family medicine, internal medicine, surgery, orthopedics (sports medicine), dermatology, medical cosmetology, dentistry, gynecology, pediatrics, ophthalmology, anesthesiology, rehabilitationmedicine, medical imaging, laboratory, pharmacy and more. Their onsite facilities and equipment include CT, X-ray, Ultrasound, Laboratory and Operating Rooms. Their doctors come from China and across the world, enabling us to serve you in many languages including, English, Japanese, Malay, Mandarin Chinese and Cantonese.
  • Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
Show all investments...

ANRI
VC Fund · Tokyo, Tokyo, Japan · 21 investments in Asia Biotech startups

ANRI is a Japanese venture capital firm that mainly invests in seed and early-stage startups.

Show more...

Investment focus

  • Industry: Software, Medical, Health Care
  • Stage:Seed, Series A
  • Geography: Japan, United States, Indonesia

Investor stats

  • Total investments: 269
  • Round size: Seed $413k–$19M; Series A $2.3M–$41M
  • Lead/follow: 23% lead, 77% follow
  • Last fund: Likely still investing — raised $102M in 2022

Portfolio highlights

  • Any Style — Any Style develops a messaging app from voice actors that regularly sends messages via subscription. It also engages in the planning and production of audio content and the VTuber production business.
  • Chaintope — Chaintope is specializes in blockchain technology with a focus for FinTech and non-FinTech sectors.
  • Smile Robotics — Smile Robotics provides Service Robots in Japan.
Show all investments...

Linear Capital
VC Fund · Shanghai, Shanghai, China · 21 investments in Asia Biotech startups, 25 in the past 12 months

Linear Capital is a Frontier Tech Fund founded in 2014 by Harry Wang, Facebook's first Chinese R&D manager. We currently manage 10 funds with AUM of more than $2 billion.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Software, Manufacturing
  • Stage:Seed, Angel, Series A
  • Geography: China, Singapore, Switzerland

Investor stats

  • Total investments: 93
  • Round size: Seed $1.4M–$122M; Angel $1.4M–$122M; Series A $5.7M–$29M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: Likely still investing — raised $500M in 2021

Portfolio highlights

  • Zhengqi Future — Zhengqi Future focuses on developing embody intelligent robots for a 3km radius living environment.
  • Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
  • Unbounded Dynamics — Unbounded Dynamics is a robotics and embodied intelligence startup focused on developing foundational AI “brains” and operational intelligence for robots and autonomous systems aimed at industrial and B-end scenarios. It works on the coordination of perception (“eyes”), manipulation (“hands”), and decision-making (“brain”) in physical robots bybuilding general basic models and expert system integrations as part of a hardware-software architecture to enable continuous iterative evolution of embodied intelligence.
Show all investments...

Longpan Investment
VC Fund · Beijing, Beijing, China · 21 investments in Asia Biotech startups, 14 in the past 12 months

Longpan Investment is an investment firm.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Cayman Islands

Investor stats

  • Total investments: 43
  • Round size: Seed $14M–$60M; Series A $14M–$30M; Series B $14M–$37M
  • Lead/follow: 56% lead, 44% follow

Portfolio highlights

  • Jingling Zhikang — Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics.
  • Hanyue New Materials — Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions.
  • Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Show all investments...

UntroD Capital
VC Fund · Sumida, Tokyo, Japan · 20 investments in Asia Biotech startups, 14 in the past 12 months

UntroD Capital is an R&D-based innovative technology that specializes in social implementation.

Show more...

Investment focus

  • Industry: Manufacturing, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: Japan, Singapore, Austria

Investor stats

  • Total investments: 138
  • Round size: Seed $772k–$28M; Series A $2.3M–$90M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

  • CastBio — Castbio specializes in antibody-drug conjugate-based drug discovery research and development. Along with medications, it also creates research reagents, medical equipment, in vitro diagnostic items, and offers drug discovery consulting.
  • Eco-Pork — Eco-Pork is a co-creation solution farm that supports farmers' food productivity improvement. It is connecting the pig and technology, pork ( Pork ) new business ecosystems ( Ecosystem By building a), in the pork growing demand around the world, to get the most out of the food supply capacity is finite.
  • IGrid Solutions — IGrid Solutions will promote “eDCM” to optimize power energy demand.
Show all investments...

Shenzhen Capital Group
VC Fund · Shenzhen, Guangdong, China · 19 investments in Asia Biotech startups

Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.

Show more...

Investment focus

  • Industry: Manufacturing, Health Care, Software
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Japan

Investor stats

  • Total investments: 533
  • Round size: Series A $1.6M–$156M; Series B $14M–$142M; Series C $4.3M–$156M
  • Lead/follow: 40% lead, 60% follow

Portfolio highlights

  • Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
  • Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
  • Waker Biology — Weike Bio is a gene therapy drug development company.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Green Pine Capital Partners
VC Fund · Shenzhen, Guangdong, China · 19 investments in Asia Biotech startups

Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Biotechnology, Health Care
  • Stage:Series A, Angel, Series B
  • Geography: China, United States, Canada

Investor stats

  • Total investments: 206
  • Round size: Angel $425k–$7.4M; Series A $1.4M–$92M; Series B $14M–$150M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — raised $138M in 2019

Portfolio highlights

  • Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
  • Sungen Biomedical — Sungen Biomedical is an innovative antibody drug R&D enterprise. It has established international standard technology platforms and original biological macromolecular R&D pipelines. Their focus includes therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, and more.
  • Canchen Technology — Canchen Tech is a technology company that focuses on the research and development of cell engineering technology in the life sciences field .The company has developed a system-level virtual organ spatiotemporal dynamic evolution model to construct a cross-scale digital twin system for life data. The platform simulates dynamic interactions frommolecules, cells, tissues to organs, and uses algorithms to simulate and deduce evolutionary processes. Its core business is used for preclinical developmental toxicity evaluation of new drugs, target discovery for rare diseases, and early screening of newborn diseases. This technical approach aims to replace and reduce some traditional in vivo animal experiments through data feedback and virtual simulation.
Show all investments...

CDH Investments
VC Fund · Kowloon City, Kowloon, Hong Kong · 19 investments in Asia Biotech startups

CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.

Show more...

Investment focus

  • Industry: Manufacturing, Health Care, Biotechnology
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, Canada

Investor stats

  • Total investments: 298
  • Round size: Series A $7.3M–$100M; Series B $14M–$142M; Series C $30M–$220M
  • Lead/follow: 47% lead, 53% follow

Portfolio highlights

  • HitGen — HitGen is provides biological reagents and services to support drug discovery research.
  • PaXini Tech — All Scenario Application—Haptic Digitization and Tactile Technology
  • Eyegood Ophthalmic Hospital — Eyegood Ophthalmic Hospital is a ophthalmology hospital.
Show all investments...

Highlight Capital
VC Fund · Nanjin, Jiangsu, China · 19 investments in Asia Biotech startups, 34 in the past 12 months

Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, South Korea

Investor stats

  • Total investments: 172
  • Round size: Seed $10M–$84M; Series A $2.8M–$74M; Series B $7.6M–$70M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: Likely still investing — raised $563M in 2021

Portfolio highlights

  • Approaching.AI — Approaching.AI is an AI Infra company focusing on the important large model application scenarios such as RAG.
  • PoShell Robotics — PoShell Robotics is a general-purpose home robot, aiming to create a home-friendly and structurally stable robot.
  • Xingyuan Zongheng Network Technology — Beijing Xingyuan Zongheng Network Technology is an aerospace and satellite internet enterprise. The company focuses on high-tech satellite system development, constellation networking, and commercial operations.
Show all investments...

Osaka University Venture Capital
VC Fund · Osaka, Osaka, Japan · 18 investments in Asia Biotech startups

Osaka University Venture Capital is a venture capital firm that focuses on early-stage ventures in the fields of life innovation, green innovation, and platform technology. The firm was founded in 2014 and based in Osaka, Japan.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: Japan

Investor stats

  • Total investments: 89
  • Round size: Seed $1.8M–$43M; Series A $3M–$49M
  • Lead/follow: 34% lead, 66% follow

Portfolio highlights

  • JiMED — JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication.
  • LQUOM — QWAVE offers cryptography communication technology.
  • Toregem BioPharma — Toregem BioPharma is a startup from Kyoto University that develops a treatment for congenital adentia. Toregem BioPharma is headquartered in Kyoto, Japan.
Show all investments...

Puhua Capital
VC Fund · Hangzhou, Zhejiang, China · 18 investments in Asia Biotech startups

Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.

Show more...

Investment focus

  • Industry: Health Care, Medical, Manufacturing
  • Stage:Series A, Series B, Seed
  • Geography: China, United Kingdom, United States

Investor stats

  • Total investments: 257
  • Round size: Seed $2.3M–$29M; Series A $1.4M–$42M; Series B $2.8M–$103M
  • Lead/follow: 34% lead, 66% follow

Portfolio highlights

  • XY TECH — Energy
  • Ganzhicao Technology — Gancao Doctor is an internet-based Traditional Chinese Medicine (TCM) company that helps clinics modernize their digital management and optimize operations. By using AI-assisted features, it enhances doctors' diagnostic and treatment abilities, delivering valuable benefits to doctors, patients, and clinics.
  • Interstellar Lightyear — Interstellar Lightyear Technology is a developer specializing in dexterous robotic hands, focusing on creating intelligent dexterous hands with advanced capabilities for precise manipulation.
Show all investments...

TF Capital
VC Fund · Pudong, Shandong, China · 18 investments in Asia Biotech startups, 6 in the past 12 months

TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: China, United States

Investor stats

  • Total investments: 63
  • Round size: Series A $10M–$120M; Series B $11M–$110M; Series C $7M–$1.4B
  • Lead/follow: 11% lead, 89% follow

Portfolio highlights

  • QL Biopharma — QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases.
  • Vivatides Therapeutics — Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.
  • Angitia Biopharmaceuticals — Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.
Show all investments...

Fast Track Initiative, Inc.
VC Fund · Hongo, Tokyo, Japan · 18 investments in Asia Biotech startups, 10 in the past 12 months

Fast Track Initiative is a venture capital firm with an exclusive focus on life sciences and healthcare services.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Seed
  • Geography: Japan, United States, United Kingdom

Investor stats

  • Total investments: 83
  • Round size: Seed $345k–$117M; Series A $3M–$113M; Series B $9.5M–$91M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: May invest from a new fund soon — raised $1.1B in 2021

Portfolio highlights

  • NovAccel — NovAccel operates as a deep tech company, ensure a stable supply of medical radioisotopes.
  • Storm Therapeutics — Targeting pathways that modify RNA to deliver novel cancer therapeutics.
  • Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Show all investments...

Hillhouse Investment
VC Fund · Changyang, Beijing, China · 18 investments in Asia Biotech startups

Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 331
  • Round size: Series A $2.9M–$157M; Series B $15M–$230M; Series C $15M–$220M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: May invest from a new fund soon — raised $11B in 2018

Portfolio highlights

  • Sainte — Sainte is a company which provides professional nutritional solutions for babies with different nutritional needs
  • Vita Dynamics — Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently.
  • NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Show all investments...

Gaorong Capital
VC Fund · Wangjing, Beijing, China · 17 investments in Asia Biotech startups

Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.

Show more...

Investment focus

  • Industry: Information Technology, Software, Artificial Intelligence
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 291
  • Round size: Seed $4.1M–$62M; Series A $2.8M–$75M; Series B $14M–$110M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: May invest from a new fund soon — raised $1.2B in 2020

Portfolio highlights

  • Genta Kyushu Bio — Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies.
  • Cascade — Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation.
  • Mochi Intelligence — Mochi Intelligence is a high-tech enterprise specializing in the research and development of embodied intelligent robots. The company is committed to creating intelligent robots including humanoid robots that can truly understand and adapt to the real world through cutting-edge artificial intelligence technology and robotics.
Show all investments...

Delian Capital
VC Fund · Beijing, Beijing, China · 17 investments in Asia Biotech startups, 13 in the past 12 months

Founded in 2011, Delian Capital specializes in the field of tech-driven industry such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterpriseservices, healthcare, etc.Examples of their investment portfolio: YueBoo、Hunan zhongli、Esafenet、Venus MedTech、MicuRx、Rokae、 IMI、12 Sigma Technologies.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Manufacturing
  • Stage:Series A, Seed, Series B
  • Geography: China, United States, France

Investor stats

  • Total investments: 97
  • Round size: Seed $1.5M–$50M; Series A $1.6M–$19M; Series B $9.9M–$29M
  • Lead/follow: 28% lead, 72% follow

Portfolio highlights

  • BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
  • Genrobot.ai — Genrobot.ai develops AI-powered robots for automation, data analysis, and intelligent task management across industries.
  • Gnosis Healthineer — Gnosis Healthineer provides medical devices to hospitals such as Clinical EEG AI Model. It builds an EEG data center for second- and third-level general hospitals to solve the problem of insufficient EEG data storage. The hardware construction of the data center includes: PB-level storage and servers, and high-performance computing equipment.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Addor Capital
VC Fund · Nanjing, Jiangsu, China · 17 investments in Asia Biotech startups

Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.

Show more...

Investment focus

  • Industry: Manufacturing, Semiconductor, Electronics
  • Stage:Series A, Series B, Seed
  • Geography: China, Hong Kong, Singapore

Investor stats

  • Total investments: 344
  • Round size: Seed $1.4k–$14M; Series A $1.6M–$43M; Series B $13M–$47M
  • Lead/follow: 50% lead, 50% follow

Portfolio highlights

  • Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
  • Beta Infinite — Beta Infinite approaches data and model technologies in a distinctive and distinctive way.
  • Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
Show all investments...

Cowin Capital
VC Fund · Shenzhen, Guangdong, China · 16 investments in Asia Biotech startups

Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.

Show more...

Investment focus

  • Industry: Manufacturing, Health Care, Biotechnology
  • Stage:Series A, Series B, Seed
  • Geography: China, Hong Kong, United States

Investor stats

  • Total investments: 327
  • Round size: Seed $1.4M–$20M; Series A $4.3M–$51M; Series B $2.8M–$50M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: May invest from a new fund soon — raised $75M in 2014

Portfolio highlights

  • Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
  • Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
  • Huachen Core Light — Huachen Core Light is a semiconductor technology company that produces and manufactures optical communications and laser chips.
Show all investments...

Prox Ventures
VC Fund · Shanghai, Shanghai, China · 16 investments in Asia Biotech startups, 7 in the past 12 months

Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.

Show more...

Investment focus

  • Industry: Medical, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: China, United States, United Kingdom

Investor stats

  • Total investments: 81
  • Round size: Seed $2.5M–$14M; Series A $2.8M–$28M
  • Lead/follow: 19% lead, 81% follow

Portfolio highlights

  • Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
  • Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
  • Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Show all investments...

Pan-Lin Capital
VC Fund · Shanghai, Shanghai, China · 16 investments in Asia Biotech startups, 7 in the past 12 months

Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors.As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors.Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Seed, Series B
  • Geography: China, United States, Canada

Investor stats

  • Total investments: 82
  • Round size: Seed $1.4k–$28M; Series A $297k–$37M; Series B $7.1M–$58M
  • Lead/follow: 43% lead, 57% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Lingdong Core Optics — Lingdong Core Optics is a high-tech firm that specializes in the design and implementation of silicon-based integrated optoelectronic chips.
  • UniXell Biotechnology — Yuesai Biotechnology is a new-generation cell therapy drug developer, focusing on the development of a new generation of cell therapy drugs.
  • Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Show all investments...

UTEC - The University of Tokyo Edge Capital Partners
VC Fund · Tokyo, Tokyo, Japan · 15 investments in Asia Biotech startups

UTEC-The University of Tokyo Edge Capital Partners Co., Ltd.. UTEC is a seed/early stage technology focused venture capital firm associated with The University of Tokyo.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A, Series B
  • Geography: Japan, United States, India

Investor stats

  • Total investments: 195
  • Round size: Seed $2.5M–$35M; Series A $2.8M–$64M; Series B $2.8M–$100M
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • Flosfia — FLOSFIA is a spin-off from a research of Kyoto University, specializing in film-formation by mist chemical vapor deposition (CVD). Making use of physical properties of gallium oxide (Ga2O3), FLOSFIA has devoted to development of low-loss power devices.
  • TXP Medical — TXP Medical build a next-generation medical system through acute care.
  • Startbahn — Startbahn aims to realize a richer society by providing the technology needed by artists and people involved with art all over the world. We are developing Startbahn Cert., a service that issues blockchain certificates for artworks, and promoting the development of Startrail, a blockchain infrastructure that is the basis for Startbahn Cert. We alsorun joint projects with other companies.
Show all investments...

CD Capital
VC Fund · Shanghai, Shanghai, China · 15 investments in Asia Biotech startups

CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series A, Series B, Seed
  • Geography: China, United States

Investor stats

  • Total investments: 73
  • Round size: Seed $1.4M–$15M; Series A $1.4M–$32M; Series B $7.1M–$34M
  • Lead/follow: 37% lead, 63% follow

Portfolio highlights

  • Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
  • Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
  • CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
Show all investments...

Keio Innovation Initiative
VC Fund · Tokyo, Tokyo, Japan · 14 investments in Asia Biotech startups, 13 in the past 12 months

Keio Innovation Initiative (KII) is a venture capital established by Keio University. In order to make more effective use of the research results of Keio University, we aim to contribute to the development of society by creating investment for venture companies that utilize research results and creating new industries.The key to thinking aboutJapan's future growth strategy is to utilize advanced research results of the university. In addition to GDP, in addition to GDP, Japan is the world's third largest R & D exporter in R & D expenses, but as the low growth rate shows, it has a problem in investment efficiency in research and development. There are also reports on the entrepreneurial spirit that is indispensable for creating new industries, with the lowest entrepreneurial activity rate among developed countries.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Seed
  • Geography: Japan, United Kingdom

Investor stats

  • Total investments: 90
  • Round size: Seed $826k–$50M; Series A $2.2M–$64M
  • Lead/follow: 30% lead, 70% follow
  • Last fund: May invest from a new fund soon — raised $1.4B in 2020

Portfolio highlights

  • JiMED — JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication.
  • Starlight Engine — Starlight Engine develops and commercializes fusion energy power plant technologies.
  • Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Show all investments...

Hillhouse Ventures
VC Fund · Singapore, Central Region, Singapore · 14 investments in Asia Biotech startups

Hillhouse Venture Capital is an investment institution established by Hillhouse Capital that focuses on investing in early-stage startups.

Show more...

Investment focus

  • Industry: Manufacturing, Biotechnology, Health Care
  • Stage:Series A, Series B, Seed
  • Geography: China, Singapore, Norway

Investor stats

  • Total investments: 77
  • Round size: Seed $10M–$120M; Series A $10M–$85M; Series B $14M–$99M
  • Lead/follow: 44% lead, 56% follow

Portfolio highlights

  • Yatsen Holding — Yasten provides high-quality fashion makeup products.
  • kaye technology — Kaye Technology is a company that provides automation upgrade solutions for beverage equipment.
  • Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
Show all investments...

K2VC
VC Fund · Beijing, Beijing, China · 14 investments in Asia Biotech startups, 13 in the past 12 months

K2VC (Xianfeng Evergreen) was founded in 2010, focused on early stage investment in technology start-ups in China, focus on promoting change and technological progress, innovative business models and lifestyles.

Show more...

Investment focus

  • Industry: E-Commerce, Manufacturing, Biotechnology
  • Stage:Series A, Seed, Angel
  • Geography: China, United States, Japan

Investor stats

  • Total investments: 215
  • Round size: Seed $1.5M–$14M; Angel $425k–$7M; Series A $1.4M–$50M
  • Lead/follow: 21% lead, 79% follow
  • Last fund: May invest from a new fund soon — raised $141M in 2018

Portfolio highlights

  • Quantex — Quantex is committed to focusing on the next generation of information technology and integrated circuit fields, and is dedicated to the in-depth research and development of 3.2T/6.4T photonic integrated chips (PIC), optical modules and CPO (co-packaged optics) solutions, leading the localization of high-end optical transmission chips.
  • Mofeng Technology — Mofeng Technology is a high-tech enterprise specializing in the research and development of polymer materials.
  • ChipSense Technology — ChipSense Technology is a semiconductor focused on developing high-performance chips for AI computing infrastructure. The company provides chip solutions that enable perception and efficiency management in AI computing centers, helping optimize resource utilization, operational efficiency, and intelligent management of large-scale AI computingclusters.
Show all investments...

Oriental Fortune Capital
VC Fund · Shenzhen, Guangdong, China · 14 investments in Asia Biotech startups

Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.

Show more...

Investment focus

  • Industry: Software, Manufacturing, Information Technology
  • Stage:Series A, Series B, Seed
  • Geography: China, United States

Investor stats

  • Total investments: 278
  • Round size: Seed $2.9M–$100M; Series A $1.4M–$43M; Series B $8.5M–$100M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: May invest from a new fund soon — last raise in 2015

Portfolio highlights

  • Awomo — Awomo, an AI technology service provider and focuses on the field of Physical AI, dedicated to building foundational models and intelligent systems for robots and the real world.
  • Youshu Quantum — Youshu Quantum is a deep-tech startup specializing in quantum computing software, middleware, and proprietary algorithms.
  • Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Baidu Ventures
VC Fund · Beijing, Beijing, China · 14 investments in Asia Biotech startups

Doma Protocol is a purpose-built blockchain to modernize and unlock the liquidity of over 362M existing and future domains

Show more...

Investment focus

  • Industry: Artificial Intelligence, Health Care, Biotechnology
  • Stage:Series A, Seed, Series B
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 225
  • Round size: Seed $1.9M–$28M; Series A $1.4M–$43M; Series B $8M–$145M
  • Lead/follow: 23% lead, 77% follow

Portfolio highlights

  • Kebotix — Kebotix is a high-tech materials discovery and production company. It is to reinvent the materials industry and enable a new age of discovery of new materials using AI, machine learning, and robotics. Kebotix is just coming out of stealth mode. It was founded in 2017 and is headquartered in Cambridge, Massachusetts.
  • Numerion Labs — Our AI superplatform explores chemical space for novel molecules, enhancing drug discovery using machine learning to uncover unseen potential.
  • Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
Show all investments...

Shunwei Capital
VC Fund · Beijing, Beijing, China · 14 investments in Asia Biotech startups

Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.

Show more...

Investment focus

  • Industry: Manufacturing, Software, Internet
  • Stage:Series A, Series B, Series C
  • Geography: China, United States, India

Investor stats

  • Total investments: 489
  • Round size: Series A $1.4M–$41M; Series B $8.2M–$58M; Series C $20M–$130M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $1.2B in 2018

Portfolio highlights

  • Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/7a5aSCUfnr https://t.co/x14hb3jO7O
  • Darma — DARMA - Digital Healt
  • Heluo New Image — Heluo New Image is a cell treatment platform developer that focuses on iPSC directed differentiation, gene editing, large-scale cell product production, and cell therapy technology development.
Show all investments...

Beijing Huafang Investment
VC Fund · Beijing, Beijing, China · 14 investments in Asia Biotech startups, 8 in the past 12 months

Beijing Huafang Investment focuses on the investment and management of state-owned capital and its investment covers commercial real estate.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Biopharma
  • Stage:Series A, Seed, Angel
  • Geography: China

Investor stats

  • Total investments: 26
  • Round size: Seed $13M–$14M; Series A $14M–$30M
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • ClonOrgan — ClonOrgan has developed a technology to humanize pig cells that will grow into human-compatible organs.The business specializes in xenotransplantation and has a one-stop R&D platform that includes raising gene-edited pigs, preclinical testing, and breeding. It is dedicated to addressing the critical shortage of clinical organ transplantationand creating the organ factory of the future.ClonOrgas was established in 2005 in Chengdu, Sichuan.
  • Kaiwang Data — Kaiwang Data is a one-stop shop for data solutions. It focuses on offering complete data labeling solutions for automakers and businesses involved in autonomous driving.
  • Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Show all investments...

Legend Star
VC Fund · Beijing, Beijing, China · 14 investments in Asia Biotech startups, 15 in the past 12 months

Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Seed, Angel
  • Geography: China, United States, France

Investor stats

  • Total investments: 156
  • Round size: Seed $1.4M–$19M; Angel $425k–$49M; Series A $1.4M–$52M
  • Lead/follow: 23% lead, 77% follow
  • Last fund: May invest from a new fund soon — raised $109M in 2018

Portfolio highlights

  • Yuanhao Power — The primary focus of Yuanhao Power, an AI native technology developer, is the creation of fifth-generation multimodal 4D world model base models. It creates a cohesive model system that encompasses dynamic environment reconstruction, generation, simulation, and intelligent agent training, and it encourages its use in applications like autonomousdriving, medical procedures, games and movies, and embodied intelligence. For the era of physical AI, it is dedicated to developing a universal world model base.
  • Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
  • Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Show all investments...

Taiyu Investment
VC Fund · 14 investments in Asia Biotech startups, 9 in the past 12 months

Taiyu Investment is an investment firm.

Show more...

Investment focus

  • Industry: Medical, Health Care, Biotechnology
  • Stage:Seed, Series A, Angel
  • Geography: China

Investor stats

  • Total investments: 43
  • Round size: Seed $4.1M–$20M; Series A $13M–$29M
  • Lead/follow: 21% lead, 79% follow

Portfolio highlights

  • Immunocan — JAWA138 memimpin di garis depan Inovasi Sistem Permainan Digital dengan fokus pada transparansi dan keadilan, terutama melalui Mekanisme RTP (Return to Player) yang Akurat.
  • Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
  • Infineon Multiomics — Infineon Multiomics is a biotechnology company that provides research and application of space multiomics technology.
Show all investments...

Cowin Venture
VC Fund · Beijing, Beijing, China · 14 investments in Asia Biotech startups

Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series A, Angel, Series B
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 104
  • Round size: Angel $425k–$1.4M; Series A $1.4M–$25M; Series B $2.8M–$257M
  • Lead/follow: 22% lead, 78% follow

Portfolio highlights

  • CytoChip — Our journey began with a research project to develop a portable blood cell testing device for astronauts on space missions. Today, we are bringing that cutting-edge technology down to Earth to transform point-of-care diagnostics, from hospitals and clinics to pharmacies and home care. After nine years of development, CytoChip’s first product,CitoCBC®, is ready for launch. Using just one drop of blood, CitoCBC® delivers lab-quality CBC results within minutes, offering accuracy comparable to central laboratory analyzers at the point of care.At our core, we are a team of passionate engineers and scientists spanning two continents, united by a singular goal: to make reliable, affordable diagnostics accessible to more people worldwide. Our headquarters and R&D centerare located in California, USA, while our engineering and manufacturing center is based in Suzhou, China. We collaborate closely with leading U.S. hospitals to advance clinical validation and innovation.Starting with the world’s first CLIA Waived cartridge-based CBC, we are committed to tackling the toughest innovation challenges in point-of-care testing. Our mission is to empower healthcare providers with reliable, cost-effective diagnostics and make data-driven testing more accessible to patients and consumers.
  • Genta Kyushu Bio — Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies.
  • StringMotion Future — StringMotion Future focuses on the core technology research and development of tendon-inspired chord-driven robots, creating advanced robotic systems designed to deliver greater flexibility, precision, and efficiency for industrial and intelligent automation applications.
Show all investments...

SDIC Venture Capital
VC Fund · Xicheng, Hebei, China · 14 investments in Asia Biotech startups, 9 in the past 12 months

ounded in 2016, SDIC Venture Capital Co., Ltd. (SDICVC) is a fund management company founded by the State Development and Investment Corp. (SDIC), under a market driven governance structure. SDICVC currently manages four funds, with total asset under management at RMB 14 Billion.SDICVC puts into practice the marketization and industrializationof the nation’s scientific and technological achievements, focusing on an investment strategy of "serving the national innovation strategy and focusing on the transformation of scientific and technological achievements". SDICVC puts its expertise and experience to work to achieve its goals of policy orientation and return on investment, faithfully implementing the national development strategy, striving to realize the synergy between the government, the society and the market, realizing its positioning as "an ideal, trustworthy, respected, influential partner” and its role as a leading professional venture fund management institution.

Show more...

Investment focus

  • Industry: Manufacturing, Biotechnology, Electronics
  • Stage:Series B, Series A, Series C
  • Geography: China, United States, Hong Kong

Investor stats

  • Total investments: 166
  • Round size: Series A $8.5M–$100M; Series B $2.8M–$129M; Series C $14M–$58M
  • Lead/follow: 54% lead, 46% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Parylene — Parylene is a provider of protective coating application solutions
  • Alnan Aluminium — Professional aluminium profile manufacturer from China, offering quality aluminium profile with reasonable price.
  • Huaguan Biotechnology — Huaguan Biotechnology provides high-quality integrated drug research and development services for customers. This includes Sihuan Pharmaceutical, Sichuan Kelun, Tianjin Tasly, Beijing Yabao, Huasu Pharmaceutical, and other well-known domestic pharmaceutical companies, as well as Suzhou Amate, Shanghai Fuqi, Jiangsu Ya Sheng, and other scientificand technological innovation enterprises, the team development ability has been recognized by the industry and has attracted a number of listed companies such as Sihuan Pharmaceutical to inject capital.
Show all investments...

JAFCO
VC Fund · Tokyo, Tokyo, Japan · 13 investments in Asia Biotech startups

Since its founding in 1973, JAFCO has always worked with leading-edge entrepreneurs. The total capital commitments of its investment funds in Japan and overseas have exceeded 1 trillion yen and the number of portfolio IPOs to date has reached over 1,000. In addition to venture investment, JAFCO also carries out buyout investment and commit to thecreations of innovative technologies and services worldwide. As entrepreneurs’ closest partner in bringing their visions to life, JAFCO provides support in areas of HR, marketing/ sales, and back-office operations, in addition to providing financing.

Show more...

Investment focus

  • Industry: Information Technology, Software, Artificial Intelligence
  • Stage:Series A, Series B
  • Geography: Japan, United States, Israel

Investor stats

  • Total investments: 304
  • Round size: Series A $2.1M–$142M; Series B $6.4M–$198M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • ADiXi — Adixi is a tech-driven business that supports the idea that people and technology may work together. It strives to open doors by utilizing cutting-edge technology, such as artificial intelligence, to promote long-term, sustainable corporate and societal progress.
  • Alxtal — Alxtal is a tech company who optimize the development, design, and manufacturing processes of the manufacturing industry with IT and AI.
  • Yokohama Vanilla — Yokohama Vanilla is a Company which operates Yokohama-based gift sweets brand.
Show all investments...

BioTrack Capital
VC Fund · Shanghai, Shanghai, China · 13 investments in Asia Biotech startups

BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Seed
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 93
  • Round size: Seed $16M–$168M; Series A $14M–$45M; Series B $15M–$147M
  • Lead/follow: 32% lead, 68% follow

Portfolio highlights

  • Huihe Healthcare — Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
  • LaNova Medicines — LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
  • Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
Show all investments...

ZhenFund
VC Fund · Beijing, Beijing, China · 13 investments in Asia Biotech startups

ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Software, E-Commerce
  • Stage:Series A, Seed, Angel
  • Geography: China, United States, Singapore

Investor stats

  • Total investments: 394
  • Round size: Seed $650k–$20M; Angel $425k–$21M; Series A $1.4M–$23M
  • Lead/follow: 17% lead, 83% follow
  • Last fund: Likely still investing — raised $130M in 2022

Portfolio highlights

  • Ehang — Ehang is a technology enterprise focused on R&D and production in airplane and aircraft field. With the combination of software and hardware techniques, it self-developed the communication and real-time viewing hardware and a smartphone operation system. Its product, Ghost, is accepted as the first truly smartphone app operated intelligentrobot, which is widely used in geographical information surveying, professional television aerial filming, roadshow displaying, disaster rescuing and delivery, surveillance and monitoring, and even expected to play important role in the future logistics areas.Ehang was founded in 2014 by makers from China, America, and Singapore who are enthusiastic about drone flying. The enterprise’s core members graduated from Tsinghua University, Peking University, and Duke University in America.
  • ImageDT — ImageDT is a Enterprise services company.
  • Futuring Robot — Futuring Robot is a developer of dual-arm home service robots focusing on C-end home scenarios.
Show all investments...

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotech Investors in Asia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 48,091 investors investing in Asia Biotech startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists